US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Invesco Nasdaq Biotechnology ETF

34.37

-0.0500-0.15%

Post-market: 34.370.00000.00%19:30 EDT

Volume:134.91K

Turnover:4.64M

Market Cap:105.52M

PE:- -

High:34.78

Open:34.78

Low:34.20

Close:34.42

52wk High:36.84

52wk Low:25.00

Shares:3.07M

Float Shares:3.07M

Volume Ratio:2.41

T/O Rate:4.39%

Dividend:0.39

Dividend Rate:1.14%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial

MT Newswires Live

Changchun High-Tech Receives Acceptance Notice for Clinical Trial Application of RSV Antibody Combination Injection

Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study

Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria

Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria

THOMSON REUTERS

Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts

THOMSON REUTERS

Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial

THOMSON REUTERS

Changchun Bcht Biotechnology Wins Acceptance for RSV Antibody Trial Application

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

Yahong Meditech's APL-2501 Doses First Patient in Phase I Study for Advanced Solid Tumors

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Orient Securities: Innovative Drugs Achieve Multi-Path Breakthroughs as Domestic Innovation Redefines Treatment Standards

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Drug Innovation and Property Sectors Rally Together! Hong Kong Stock Connect Innovation Drug ETF's Underlying Index Spikes Up to 6.15% Intraday! Real Estate Surges for a Second Straight Day, Vanke A and Greenland Holdings Notch Consecutive Limit-Ups!

Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594

THOMSON REUTERS

Fund Manager Cites AI Drug Development Momentum and Export Growth as Key Drivers for Pharmaceutical Sector Opportunities

Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection

ETF Market Wrap for September 21: Policy Tailwinds and Clearer Outbound Channels Lift Innovative Drug Funds, While Crypto ETFs Surge Throughout the Day

Hong Kong Equities Close Higher | Hang Seng Index Regains 25,000 Mark, Innovative Drug Shares Rally Broadly, SBP Group Tops Blue-Chip Gainers

Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/IBBQ/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.37,"timestamp":1790971200000,"preClose":34.42,"halted":0,"volume":134914,"hourTrading":{"tag":"盘后","latestPrice":34.37,"preClose":34.37,"latestTime":"19:30 EDT","volume":23,"amount":793.71,"timestamp":1790983804820,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0014526438117374858,"floatShares":3070000,"shares":3070000,"eps":0,"marketStatus":"Market Closed","change":-0.05,"latestTime":"10-02 16:00:00 EDT","open":34.78,"high":34.78,"low":34.2,"amount":4640242.504378,"amplitude":0.016851,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":34.42,"sharesOutstanding":2520001,"nav":34.4248,"aum":106440372.14,"dividendRate":0.01135,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.5,"preClose":34.42,"latestTime":"07:58 EDT","volume":100,"amount":3450,"timestamp":1790942314618,"change":0.08,"changeRate":0.002324,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":34.37,"preClose":34.37,"latestTime":"19:30 EDT","volume":23,"amount":793.71,"timestamp":1790983804820,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":2.412124809157592,"impliedVol":0.1226,"impliedVolPercentile":0.5299},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":3070000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.412124809157592,"shares":3070000,"dividePrice":0.3901,"high":34.78,"amplitude":0.016851,"preClose":34.42,"low":34.2,"week52Low":25,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.37,"eps":0,"divideRate":0.01135,"volume":134914,"delay":0,"ttmEps":0,"open":34.78,"prevYearClose":28.3962,"prevWeekClose":35,"prevMonthClose":35.14,"prevQuarterClose":35.14,"fiveDayClose":35,"twentyDayClose":36.26,"sixtyDayClose":33.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-09-21","symbol":"IBBQ","amount":0.23037,"announcedDate":"2026-09-18","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-21","defaultRemindTime":1789997400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-25","payableDate":"2026-09-21","currency":"USD","dateTimestamp":1789963200000,"payDate":"2026-09-25"},{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669425861","title":"Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669425861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669425861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:50","pubTimestamp":1790081406,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  said Tuesday that a phase 2b study of inaxaplin to treat patients with APOL1-mediated kidney disease showed a 42.7% protein reduction, and a 17.3% reduction in patients who also have type 2 diabetes.The company said the drug showed a favorable safety profile with no drug-related serious adverse events reported. It said headaches were the most frequent side effect, which affected 7.3% of trial participants.The company said the reduction was measured after 13 weeks of treatment. Vertex said it has finished enrolling patients in a larger Phase 2/3 trial of inaxaplin.Shares of Vertex were up 2.2% pre-bell.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","IE00BZ9MQY76.HKD","IE0009355771.USD","SG9999001176.USD","LU1674673428.USD","IE00B19Z9P08.USD","LU0757428866.USD","IE00B19Z3581.USD","LU2236285917.USD","LU2468319806.SGD","BK4532","LU2089984988.USD","BBH","BK4139","BK4567","LU1559883803.SGD","LU1778281490.HKD","BK4023","TBXU","LU0061475181.USD","IE0002141913.USD","SGXZ57979304.SGD","SG9999013999.USD","IDNA","LU2417539215.USD","IE00BJJMRZ35.SGD","GNMX","PBE","IE0002270589.USD","LU1069344957.HKD","IE00BJT1NW94.SGD","LU1093756325.SGD","BK4533","LU2324357040.USD","LU0566484027.USD","LU2362540622.SGD","LU1035775433.USD","IE00B894F039.SGD","LU0058720904.USD","IBBQ","SG9999001176.SGD","VRTX","IE00B19Z9Z06.USD","LU1674673691.USD","BIB","LU0079474960.USD","BK4588","VERX","LU2362541513.USD","LU1815336091.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181632018","title":"Changchun High-Tech Receives Acceptance Notice for Clinical Trial Application of RSV Antibody Combination Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1181632018","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181632018?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:34","pubTimestamp":1790080464,"startTime":"0","endTime":"0","summary":"Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ) announced that its subsidiary, Changchun Baike Biological Technology Co., Ltd. (\"Baike Bio\"), recently received the \"Acceptance Notice\" from...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0057","IBBJ","IBBQ","MDTX","BMED","BK0075","PSYK","BK0046","BK0028","BK0239","000661"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669144313","title":"Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study","url":"https://stock-news.laohu8.com/highlight/detail?id=2669144313","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669144313?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:15","pubTimestamp":1790079331,"startTime":"0","endTime":"0","summary":"The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-announces-positive-results-from-phase-2b-inaxaplin-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFTCPJ56.SGD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU0061475181.USD","LU1585245621.USD","IE00B19Z9Z06.USD","IBBQ","IE0009355771.USD","LU2089984988.USD","LU2237438978.USD","BIB","IE00BJT1NW94.SGD","SG9999013999.USD","LU0432979614.USD","VERX","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","IE00B19Z9P08.USD","LU1674673428.USD","LU1815336091.USD","IE0002141913.USD","BK4532","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","LU0289739699.SGD","BBH","IE00B2B36J28.USD","LU1035775433.USD","TBXU","IBB","IE00B19Z3581.USD","LU0109394709.USD","SG9999001176.SGD","BK4139","LU0757428866.USD","LU0823416689.USD","LU2236285917.USD","BK4567","BK4023","LU1674673691.USD","BK4588","IDNA","LU1093756168.USD","LU2362540622.SGD","PBE","VRTX","LU0320765992.SGD","LU0256863811.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669177141","title":"Vertex Says Phase 2b Amplified Study Shows Inaxaplin Cuts Proteinuria in APOL1-Mediated Kidney Disease Patients with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669177141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669177141?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:02","pubTimestamp":1790078577,"startTime":"0","endTime":"0","summary":"Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuriaVertex reported positive Phase 2b AMPLIFIED results for inaxaplin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL8CHhBr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089984988.USD","IE00B19Z9P08.USD","BK4139","IBBQ","LU1093756168.USD","BK4567","IBB","IDNA","IE00BJT1NW94.SGD","SG9999001176.SGD","BIB","LU2462157665.USD","IE00BFTCPJ56.SGD","IE0002270589.USD","LU1069344957.HKD","LU2362541273.HKD","BBH","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1674673691.USD","LU0320765992.SGD","LU0061475181.USD","LU2468319806.SGD","LU1093756325.SGD","SG9999013999.USD","LU0256863811.USD","LU0058720904.USD","BK4585","LU2324357040.USD","LU0432979614.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","LU0079474960.USD","LU2362541513.USD","VRTX","IE0002141913.USD","BK4532","IE0009355771.USD","IE00BZ9MQY76.HKD","LU1035775433.USD","LU2237438978.USD","TBXU","LU1674673428.USD","BK4588","LU0823416689.USD","LU0109394709.USD","IE00B2B36J28.USD","IE00B19Z9Z06.USD","GNMX","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419861","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Reduces Uacr by -42.7% at Week 13 in Amkd with Modest Proteinuria","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419861?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","VRTX","BBH","IBBQ","IE00B2B36J28.USD","PBE","BK4139","IE00BJJMRZ35.SGD","LU0256863811.USD","IE00B19Z3581.USD","LU1674673691.USD","LU2417539215.USD","LU2456880835.USD","IBB","LU1069344957.HKD","LU2236285917.USD","LU2462157665.USD","LU1778281490.HKD","TBXU","IE0002141913.USD","IE0002270589.USD","BK4585","LU0889565916.HKD","LU2362541513.USD","SG9999001176.SGD","SGXZ57979304.SGD","LU2362541273.HKD","IE0009355771.USD","BIB","LU1585245621.USD","LU0823416689.USD","LU2237438978.USD","LU0234570918.USD","GNMX","LU1674673428.USD","IE00B19Z9P08.USD","LU1093756168.USD","IE00B894F039.SGD","LU0289739699.SGD","LU1430594728.SGD","LU0079474960.USD","LU0417517546.SGD","LU2362540622.SGD","LU2468319806.SGD","IE00B4R5TH58.HKD","LU2324357040.USD","IDNA","IE00BJT1NW94.SGD","LU1093756325.SGD","IE00B19Z9Z06.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669419041","title":"Vertex Pharmaceuticals Incorporated - Inaxaplin Generally Safe and Well Tolerated in Both Amkd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2669419041","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669419041?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0061475181.USD","LU0058720904.USD","LU1585245621.USD","IE00B19Z9Z06.USD","LU2456880835.USD","BK4533","IBBQ","LU2089984988.USD","LU2237438978.USD","IE00BJT1NW94.SGD","BIB","SG9999013999.USD","LU0432979614.USD","LU2362541273.HKD","LU1093756325.SGD","LU0234570918.USD","LU2462157665.USD","IE00B19Z9P08.USD","LU1674673428.USD","LU2324357040.USD","BK4585","IE00BZ9MQY76.HKD","IE0002141913.USD","BK4532","LU1069344957.HKD","GNMX","LU1778281490.HKD","IE00B4R5TH58.HKD","BBH","LU1035775433.USD","TBXU","IBB","LU0109394709.USD","IE0002270589.USD","LU0889565916.HKD","SG9999001176.SGD","SGXZ57979304.SGD","BK4139","LU2417539215.USD","BK4567","BK4588","IDNA","SG9999001176.USD","LU2362541513.USD","PBE","IE00BJJMRZ35.SGD","VRTX","LU0320765992.SGD","LU0256863811.USD","LU0079474960.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141954","title":"Vertex Announces Positive Results from Phase 2B Amplified Study of Inaxaplin in Additional Populations of People with Apol1-Mediated Kidney Disease (Amkd) and Completion of Enrollment in the Phase 2/3 Amplitude Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141954?lang=en_us&edition=fundamental","pubTime":"2026-09-22 20:00","pubTimestamp":1790078403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUA6RPXRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","LU2237438978.USD","LU0823416689.USD","IE00B19Z9P08.USD","LU1035775433.USD","LU0109394709.USD","LU1069344957.HKD","LU1093756325.SGD","BK4532","SG9999013999.USD","BIB","IDNA","IE00BZ9MQY76.HKD","LU2236285917.USD","IE00B4R5TH58.HKD","LU0256863811.USD","IE00B19Z3581.USD","BK4585","LU1778281490.HKD","LU1674673691.USD","LU0079474960.USD","IBB","IE0002141913.USD","IE00B2B36J28.USD","PBE","LU1585245621.USD","BK4533","LU0289739699.SGD","IE00BJT1NW94.SGD","LU1674673428.USD","LU2456880835.USD","SG9999001176.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BK4567","SGXZ57979304.SGD","VRTX","IBBQ","LU0058720904.USD","LU0320765992.SGD","LU0432979614.USD","GNMX","TBXU","BK4139","LU0234570918.USD","LU2089984988.USD","BBH","LU0061475181.USD","LU0417517546.SGD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192668896","title":"Changchun Bcht Biotechnology Wins Acceptance for RSV Antibody Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1192668896","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192668896?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:20","pubTimestamp":1790076019,"startTime":"0","endTime":"0","summary":"Changchun Bcht Biotechnology Co. (SH: 688276) has announced that it recently received the Acceptance Notice from the National Medical Products Administration regarding the clinical trial application...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","BMED","IBBQ","IBBJ","BK0239","PSYK","688276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143096","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143096?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:10","pubTimestamp":1790071809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA). ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","LU0868494617.USD","LU0058720904.USD","LU0109394709.USD","BK4139","IE00B2B36J28.USD","BK4585","LU1057294990.SGD","IE00B4R5TH58.HKD","LU0320765992.SGD","BK4599","LU1983299246.USD","AMGN","SG9999001440.SGD","BK4588","IE0002141913.USD","LU1061106388.HKD","LU2468319806.SGD","TBXU","LU0029874061.USD","BK4533","HCSG","LU1023059063.AUD","LABU","BK4539","IVVD","LU2089984988.USD","PJP","BIB","IBB","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU2242646821.SGD","LU0122379950.USD","LU1571399168.USD","BK4137","BK4566","IBBQ","LU0128526141.USD","IE0009355771.USD","LU0289739699.SGD","BK4563","XLV","XBI","LU0889565916.HKD","PBE","LU2242652126.USD","IE00BJJMRZ35.SGD","BBH","HUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109466006","title":"Yahong Meditech's APL-2501 Doses First Patient in Phase I Study for Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=1109466006","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109466006?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:46","pubTimestamp":1790070404,"startTime":"0","endTime":"0","summary":"Jiangsu Yahong Meditech Co., Ltd. (688176.SH) has officially announced that its self-developed candidate, APL-2501, has achieved first-patient dosing in a Phase I/II clinical trial targeting advanced...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688176","IBBJ","BK1161","BK1515","159938","MDTX","09939","BMED","PSYK","IBBQ","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669511784","title":"Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669511784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669511784?lang=en_us&edition=fundamental","pubTime":"2026-09-22 16:32","pubTimestamp":1790065920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 5.84 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25087.75.Sino Biopharmaceutical Ltd. closed 32% short of its 52-week high of HK$8.56, which the company reached Sept. 23.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 1.1% and Amgen Inc. remained unchanged.Trading volume totaled 87.2 million shares, compared to the 50-day average of 88.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","PBE","LU2089984988.USD","LU2242646821.SGD","IE00B2B36J28.USD","LU0122379950.USD","BK4139","IE00B4R5TH58.HKD","LU0320765992.SGD","BK1589","BIB","IE00BZ08YR35.GBP","LU2468319806.SGD","BK4534","IBB","BK4588","LU0058720904.USD","IE0002141913.USD","LU0289739699.SGD","LU1023059063.AUD","LU1061106388.HKD","LU1571399168.USD","BK4566","IE00BFTCPJ56.SGD","LU1057294990.SGD","BBH","BK1515","IE00BZ08YS42.EUR","IE00BJJMRZ35.SGD","BK4581","PJP","LU2112291526.USD","IE0009355771.USD","BK4585","LU0109394709.USD","IE00BZ08YT58.USD","AMGN","LU0889565916.HKD","BK4533","TBXU","BK4599","SG9999001440.SGD","LU1983299246.USD","HK0000165453.HKD","LU2242652126.USD","BK1521","IBBQ","LU0868494617.USD","IE00BJT1NW94.SGD","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108337067","title":"Orient Securities: Innovative Drugs Achieve Multi-Path Breakthroughs as Domestic Innovation Redefines Treatment Standards","url":"https://stock-news.laohu8.com/highlight/detail?id=1108337067","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108337067?lang=en_us&edition=fundamental","pubTime":"2026-09-22 10:34","pubTimestamp":1790044458,"startTime":"0","endTime":"0","summary":"Orient Securities has released a research report stating that the latest WCLC conference further validates that domestic innovative drugs in lung cancer have progressed from early single-arm data to...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","159992","BK0183","BK0188","BK0276","MEDX","BK1564","BK1161","BK0028","06978","03958","LNGR","BK1147","BK1574","600958","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619383","title":"Moderna Inc. Stock Climbs 12.3%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619383","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619383?lang=en_us&edition=fundamental","pubTime":"2026-09-22 04:33","pubTimestamp":1790022780,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. jumped 12.3% to $172.94 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.3% to 27,122.09 and the Dow Jones Industrial Average rising 0.7% to 52,048.83.Moderna Inc. closed 2.1% short of its 52-week high of $176.66, which the company reached on August 19th.The stock outperformed some of its peers, as Johnson & Johnson fell 0.2% to $269.47, Pfizer Inc. rose 0.3% to $27.74, and Gilead Sciences Inc. rose 0.30% to $150.56.Trading volume totaled 20.9 million, compared to the 50-day average of 17.9 million.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU2468319806.SGD","WDNA","LU1778281490.HKD","LU0965509101.SGD","LU1066053197.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","IBBQ","LU1023059063.AUD","BK4548","LU1066051498.USD","LU1430594728.SGD","BMED","IBB","LU1061106388.HKD","LU1839511570.USD","BK4533","LU0109394709.USD","BK4139","BK4532","BK4534","LU0234570918.USD","LU0859254822.USD","LU2089984988.USD","LU0320765992.SGD","LU0058720904.USD","MRNX","IDNA","IE00BSNM7G36.USD","LU1674673428.USD","BK4501","LU0889565916.HKD","SG9999015952.SGD","BK4578","MRNA","LU0122379950.USD","LU1934455194.USD","MRNY","SG9999015986.USD","GNOM","GILD","TMED","LU0861579265.USD","LGHT","LU0289739699.SGD","TBXU","BIB","BBH","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188812777","title":"Drug Innovation and Property Sectors Rally Together! Hong Kong Stock Connect Innovation Drug ETF's Underlying Index Spikes Up to 6.15% Intraday! Real Estate Surges for a Second Straight Day, Vanke A and Greenland Holdings Notch Consecutive Limit-Ups!","url":"https://stock-news.laohu8.com/highlight/detail?id=1188812777","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188812777?lang=en_us&edition=fundamental","pubTime":"2026-09-21 19:13","pubTimestamp":1789989213,"startTime":"0","endTime":"0","summary":"On September 21st, the major A-share indices closed the trading day in positive territory, with the Shanghai Composite Index opening higher and advancing nearly 1% throughout the session. More than...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0178","BK0028","BK0196","BK0012","BK1574","BK0174","LU2148510915.USD","BK0273","LU1328615791.USD","BK0157","159316","BK0180","06978","BK0187","BK0101","LU1064131003.USD","MEDX","600606","BK0188","BK0086","BK0277","BK0116","LU1064130708.USD","BK1161","LNGR","FLHK","000002","159992","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669315293","title":"Vertex Pharmaceuticals Incorporated : Leerink Partners Resumes Coverage with Outperform Rating; Target Price $594","url":"https://stock-news.laohu8.com/highlight/detail?id=2669315293","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669315293?lang=en_us&edition=fundamental","pubTime":"2026-09-21 18:03","pubTimestamp":1789985027,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0U1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","LU2456880835.USD","LU0109394709.USD","LU0061475181.USD","LU2362540622.SGD","LU2462157665.USD","TBXU","BK4567","LU2468319806.SGD","LU1093756325.SGD","LU0320765992.SGD","LU2236285917.USD","LU0058720904.USD","LU2362541273.HKD","LU1093756168.USD","IBBQ","LU1585245621.USD","LU0289739699.SGD","IDNA","PBE","IE00BJJMRZ35.SGD","GNMX","LU0823416689.USD","IE00BZ9MQY76.HKD","BK4139","LU1674673428.USD","LU2324357040.USD","LU2362541513.USD","BIB","LU0234570918.USD","IE00B19Z3581.USD","IE00B4R5TH58.HKD","BK4532","IE00B894F039.SGD","IE00BFTCPJ56.SGD","LU1035775433.USD","IBB","SG9999001176.SGD","BBH","IE00BJT1NW94.SGD","LU0256863811.USD","BK4588","LU1069344957.HKD","LU2417539215.USD","VRTX","LU1778281490.HKD","BK4533","LU2089984988.USD","SG9999013999.USD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151791583","title":"Fund Manager Cites AI Drug Development Momentum and Export Growth as Key Drivers for Pharmaceutical Sector Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=1151791583","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151791583?lang=en_us&edition=fundamental","pubTime":"2026-09-21 17:40","pubTimestamp":1789983648,"startTime":"0","endTime":"0","summary":"Li Jiacun, Deputy Director of the Investment Management Department at China Merchants Fund and manager of the China Merchants Pharmaceutical Health Industry Stock Fund, recently shared his views on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","LNGR","WX","159992","06978","CZA","LCO","NIFE","CXO","IBBQ","BK1574","REVS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174623645","title":"Jiangsu Hengrui Pharmaceuticals Secures Clinical Trial Approval for SHR-4595 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1174623645","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174623645?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:56","pubTimestamp":1789980976,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (SH: 600276) has announced that its subsidiary, Suzhou Sdiary Biopharmaceuticals Co., Ltd., recently obtained the Clinical Trial Approval Notice for the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","LU2488822045.USD","600276","LU0405327494.USD","LU2097828714.EUR","LU2289578879.USD","LU1820825898.SGD","IBBJ","BK0012","LU1781817850.SGD","LU2495084118.USD","LU0359202008.SGD","BK0183","LU1255011170.USD","LU1328615791.USD","LU1064130708.USD","LU0359201885.HKD","LU1969619763.USD","MDTX","LU1064131003.USD","LU0359201612.USD","LU2097828805.USD","LU2328871848.SGD","LU2097828631.EUR","LU0405327148.USD","LU1655091616.SGD","LU2580892789.USD","LU2148510915.USD","LU1023057109.AUD","LU2097828557.USD","BK0239","LU2097828474.EUR","BK1191","01276","LU2580892862.HKD","BK0028","BMED","PSYK","LU1146622755.USD","LU1997245094.SGD","LU1997245177.USD","BK0060","BK0196","IBBQ","LU1580142542.USD","LU2543165471.USD","LU1997244956.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108254136","title":"ETF Market Wrap for September 21: Policy Tailwinds and Clearer Outbound Channels Lift Innovative Drug Funds, While Crypto ETFs Surge Throughout the Day","url":"https://stock-news.laohu8.com/highlight/detail?id=1108254136","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108254136?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:40","pubTimestamp":1789980028,"startTime":"0","endTime":"0","summary":"Following the Federal Reserve's rate hike decision, risk appetite improved and Hong Kong stocks continued their recovery, with the pharmaceutical and biotech sector along with mainland property...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03042","FTGPF","83042","BK4585","07399","BK4588","FDN","BK1161","BK4550","MEDX","TCAN","IBBQ","BK1574","07799","159992","LTCC","BLOX","06978","BK1611","LNGR","07711","09042"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122246350","title":"Hong Kong Equities Close Higher | Hang Seng Index Regains 25,000 Mark, Innovative Drug Shares Rally Broadly, SBP Group Tops Blue-Chip Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=1122246350","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122246350?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:39","pubTimestamp":1789979997,"startTime":"0","endTime":"0","summary":"Hong Kong's three major stock indices trended upward in a choppy session on Monday, with the Hang Seng Index reclaiming the 25,000-point level. By the close, the Hang Seng Index rose 1.18%, or 291.93...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07500","IBBQ","01477","01177","06727","BK1535","HK0000165453.HKD","BK1515","BK1589","VXUS","BK1109","83115","09115","HSI","MHImain","HHImain","01918","02833","HSImain","BK1191","07630","01138","82800","BK1166","KCAI","513600","BK1555","IE00BZ08YR35.GBP","MCHmain","07200","BK1161","BK4585","MEDX","03115","IE00BZ08YT58.USD","159992","SG9999014674.SGD","06978","BK1521","BK4588","IE00BZ08YS42.EUR","03419","LNGR","07300","02800","BK1574","03037","BK1240"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156720","title":"Sino Biopharmaceutical Stock Rises 8.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156720","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669156720?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:30","pubTimestamp":1789979400,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. rallied 8.2% to 5.92 Hong Kong dollars on what proved to be an all-around great trading session for the Hong Kong stock market, with the Hang Seng Index rising 1.2% to 25042.71.Sino Biopharmaceutical Ltd. closed 32% below its 52-week high of HK$8.65, which the company achieved Sept. 22.The stock outperformed some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 7.6% and Amgen Inc. remained unchanged.Trading volume totaled 150.2 million shares, compared to the 50-day average of 89.1 million shares.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PJP","IBB","IE0009355771.USD","LU2242646821.SGD","LU0889565916.HKD","IE00B2B36J28.USD","LU0109394709.USD","LU2468319806.SGD","LU2089984988.USD","AMGN","LU1057294990.SGD","LU1571399168.USD","BBH","BK4139","LU1983299246.USD","LU0868494617.USD","TBXU","BK4581","HK0000165453.HKD","IE0002141913.USD","BK1191","IE00BZ08YT58.USD","LU2112291526.USD","LU2242652126.USD","BK4534","SG9999001440.SGD","BK4599","BK1589","IE00BZ08YR35.GBP","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","IE00BZ08YS42.EUR","PBE","IE00BJT1NW94.SGD","BK4566","BK4533","LU1023059063.AUD","01177","LU0058720904.USD","IBBQ","LU0122379950.USD","BK1521","BIB","BK1515","BK4588","IE00B4R5TH58.HKD","LU0289739699.SGD","LU0320765992.SGD","LU1061106388.HKD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}